Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update
Open Access
- 27 November 2014
- journal article
- review article
- Published by Hindawi Limited in Advances in Hematology
- Vol. 2014, 1-9
Abstract
Febrile neutropenia is one of the most serious complications in patients with haematological malignancies and chemotherapy. A prompt identification of infection and empirical antibiotic therapy can prolong survival. This paper reviews the guidelines about febrile neutropenia in the setting of hematologic malignancies, providing an overview of the definition of fever and neutropenia, and categories of risk assessment, management of infections, and prophylaxis.Keywords
This publication has 64 references indexed in Scilit:
- Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxisBMC Infectious Diseases, 2013
- Hematological: Low all‐cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a single‐center studyEuropean Journal of Haematology, 2012
- Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem‐cell transplantationBritish Journal of Haematology, 2011
- The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart ProjectHaematologica, 2011
- Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignanciesInternational Journal of Infectious Diseases, 2011
- Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantationBlood, 2010
- Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host DiseaseNew England Journal of Medicine, 2007
- Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with NeutropeniaNew England Journal of Medicine, 2007
- Antibiotic prophylaxis in neutropenic patientsCancer, 2006
- Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 2004